Alphamab Oncology (09966)
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. It
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
